Premium
Alclometasone Dipropionate Cream 0.05% Versus Clobetasone Butyrate Cream 0.05%
Author(s) -
Lassus Allan
Publication year - 1984
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/j.1365-4362.1984.tb04214.x
Subject(s) - medicine , clearance , erythema , adverse effect , dermatology , atopic dermatitis , randomized controlled trial , signs and symptoms , surgery , urology
A randomized, double‐blind, parallel‐group study was conducted comparing the efficacy and safety of alclometasone dipropionate cream 0.05% and clobetasone butyrate cream 0.05% in the treatment of atopic dermatitis in 43 children. The medications were applied to study areas as a thin layer of cream twice daily for 2 weeks. Efficacy was assessed by evaluation of three disease signs (erythema, induration, and pruritus) and by mean of a physician's global evaluation following treatment. Safety was evaluated through patient‐reported and clinically observed adverse experiences. Both treatments were effective. At the end of the trial, average reduction in disease signs was 85% for alclometasone dipropionate‐treated patients and 86% in the clobetasone butyrate‐treated group. In the global evaluation, the physician rated symptoms as cleared in 9 of 22 alclometasone dipropionate‐treated patients and in 10 of 21 clobetasone butyrate‐treated patients.